Literature DB >> 24240201

Rapid rate of peripheral blood blast clearance accurately predicts complete remission in acute myeloid leukemia.

V Vainstein1, S A Buckley2, O Shukron3, E H Estey4, J L Abkowitz5, B L Wood6, R B Walter7.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 24240201     DOI： 10.1038/leu.2013.341

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Peripheral blood blast clearance during induction therapy in acute myeloid leukemia.

Authors:  Giacomo Gianfaldoni; Francesco Mannelli; Sara Bencini; Franco Leoni; Simone Baldini; Alberto Bosi
Journal:  Blood       Date:  2008-02-01       Impact factor: 22.113

2.  Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia.

Authors:  Masamitsu Yanada; Gautam Borthakur; Farhad Ravandi; Carlos Bueso-Ramos; Hagop Kantarjian; Elihu Estey
Journal:  Haematologica       Date:  2008-06-02       Impact factor: 9.941

3.  Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia.

Authors:  Thomas Büchner; Wolfgang E Berdel; Claudia Schoch; Torsten Haferlach; Hubert L Serve; Joachim Kienast; Susanne Schnittger; Wolfgang Kern; Joelle Tchinda; Albrecht Reichle; Eva Lengfelder; Peter Staib; Wolf-Dieter Ludwig; Carlo Aul; Hartmut Eimermacher; Leopold Balleisen; Maria-Cristina Sauerland; Achim Heinecke; Bernhard Wörmann; Wolfgang Hiddemann
Journal:  J Clin Oncol       Date:  2006-06-01       Impact factor: 44.544

4.  Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study.

Authors:  Giacomo Gianfaldoni; Francesco Mannelli; Michela Baccini; Elisabetta Antonioli; Franco Leoni; Alberto Bosi
Journal:  Br J Haematol       Date:  2006-07       Impact factor: 6.998

5.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials.

Authors:  David Grimwade; Robert K Hills; Anthony V Moorman; Helen Walker; Stephen Chatters; Anthony H Goldstone; Keith Wheatley; Christine J Harrison; Alan K Burnett
Journal:  Blood       Date:  2010-04-12       Impact factor: 22.113

6.  Bone marrow aspirate on the 14th day of induction treatment as a prognostic tool in de novo adult acute myeloid leukemia.

Authors:  V Liso; F Albano; D Pastore; P Carluccio; G Mele; M Lamacchia; A Mestice; G Specchia
Journal:  Haematologica       Date:  2000-12       Impact factor: 9.941

7.  A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties.

Authors:  K Wheatley; A K Burnett; A H Goldstone; R G Gray; I M Hann; C J Harrison; J K Rees; R F Stevens; H Walker
Journal:  Br J Haematol       Date:  1999-10       Impact factor: 6.998

Review 8.  Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet.

Authors:  Hartmut Döhner; Elihu H Estey; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Alan K Burnett; Hervé Dombret; Pierre Fenaux; David Grimwade; Richard A Larson; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel A Sanz; Jorge Sierra; Martin S Tallman; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2009-10-30       Impact factor: 22.113

9.  Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival.

Authors:  Michelle A Elliott; Mark R Litzow; Louis L Letendre; Robert C Wolf; Curtis A Hanson; Ayalew Tefferi; Martin S Tallman
Journal:  Blood       Date:  2007-10-01       Impact factor: 22.113

10.  Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia.

Authors:  A Gajjar; R Ribeiro; M L Hancock; G K Rivera; H Mahmoud; J T Sandlund; W M Crist; C H Pui
Journal:  Blood       Date:  1995-08-15       Impact factor: 22.113
View more
  11 in total

1.  Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes.

Authors:  Sarah A Buckley; Megan Othus; Vladimir Vainstein; Janis L Abkowitz; Elihu H Estey; Roland B Walter
Journal:  Am J Hematol       Date:  2014-02-24       Impact factor: 10.047

Review 2.  Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.

Authors:  Mary-Elizabeth Percival; Catherine Lai; Elihu Estey; Christopher S Hourigan
Journal:  Blood Rev       Date:  2017-02-02       Impact factor: 8.250

3.  Value of routine 'day 14' marrow exam in newly diagnosed AML.

Authors:  T Yezefski; H Xie; R Walter; J Pagel; P S Becker; P Hendrie; V Sandhu; K Shannon-Dorcy; J Abkowitz; F R Appelbaum; E Estey
Journal:  Leukemia       Date:  2014-09-10       Impact factor: 11.528

4.  Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy.

Authors:  Nicholas J Short; Christopher B Benton; Hsiang-Chun Chen; Peng Qiu; Lisa Gu; Sherry Pierce; Mark Brandt; Abhishek Maiti; Taejin L Min; Kiran Naqvi; Alfonso Quintas-Cardama; Marina Konopleva; Tapan Kadia; Jorge Cortes; Guillermo Garcia-Manero; Farhad Ravandi; Elias Jabbour; Hagop Kantarjian; Michael Andreeff
Journal:  Am J Hematol       Date:  2016-08-29       Impact factor: 10.047

5.  Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission.

Authors:  Roland B Walter; Brenda M Sandmaier; Barry E Storer; Colin D Godwin; Sarah A Buckley; John M Pagel; Mohamed L Sorror; H Joachim Deeg; Rainer Storb; Frederick R Appelbaum
Journal:  Biol Blood Marrow Transplant       Date:  2014-09-30       Impact factor: 5.742

6.  Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia.

Authors:  M Othus; B L Wood; D L Stirewalt; E H Estey; S H Petersdorf; F R Appelbaum; H P Erba; R B Walter
Journal:  Leukemia       Date:  2016-05-02       Impact factor: 11.528

7.  [Expert consensus on minimal residual disease detection of acute leukemia and plasma cell neoplasms by multi-parameter flow cytometry].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-12-14

8.  Molecular Measurable Residual Disease Testing of Blood During AML Cytotoxic Therapy for Early Prediction of Clinical Response.

Authors:  Hong Yuen Wong; Anthony D Sung; Katherine E Lindblad; Sheenu Sheela; Gregory W Roloff; David Rizzieri; Meghali Goswami; Matthew P Mulé; Nestor R Ramos; Jingrong Tang; Julie Thompson; Christin B DeStefano; Kristi Romero; Laura W Dillon; Dong-Yun Kim; Catherine Lai; Christopher S Hourigan
Journal:  Front Oncol       Date:  2019-01-15       Impact factor: 6.244

9.  The Impact of Early Versus Late Platelet and Neutrophil Recovery after Induction Chemotherapy on Survival Outcomes of Patients with Acute Myeloid Leukemia

Authors:  Rafiye Çiftçiler; İbrahim C. Haznedaroğlu; Nilgün Sayınalp; Osman Özcebe; Salih Aksu; Haluk Demiroğlu; Hakan Göker; Ümit Yavuz Malkan; Yahya Büyükaşık
Journal:  Turk J Haematol       Date:  2019-09-02       Impact factor: 1.831

10.  The prognostic value of the peripheral blood cell counts changes during induction chemotherapy in Chinese patients with adult acute myeloid leukemia.

Authors:  Yuan-Mao Huang; Yan-Ni Wang; Yi Zheng; Li-Li Pan; Yang Li; Jing-Gang Li; Shao-Yuan Wang
Journal:  Medicine (Baltimore)       Date:  2021-02-26       Impact factor: 1.817
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.